Search

… is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called …

… Announces Year End 2024 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across … transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its …

… targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to … for cardiovascular diseases, and progress made across the Axiomer platform €89.4 million cash and cash equivalents as …

… Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues … with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing … against our strategy to accelerate the development of Axiomer,” said Daniel A. de Boer, Chief Executive Officer of …

… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced an … in MECP2 gene, and is based on ProQR’s proprietary Axiomer RNA editing platform. Axiomer can target many …

… strategy to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across … RNA editing technology – Accelerate development of the Axiomer ® RNA base-editing technology platform, including an … The Company will accelerate the development of its Axiomer ® RNA editing platform and pipeline activities and …

… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … seen firsthand the transformative potential of ProQR’s Axiomer RNA editing platform. I am excited to join the …

… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …